Online inquiry

IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1937MR)

This product GTTS-WQ1937MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLITRK6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_032229.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84189
UniProt ID Q9H5Y7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1937MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4582MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ6446MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ3581MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ7929MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ775MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ13465MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ14850MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ425MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 3C23K
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW